Material
R egulatory T cells (Treg)
3 are negative regulators of immune responses to self and foreign Ags and are critical for maintaining immune tolerance (1-3). Although extensive studies have focused on the CD4 ϩ CD25 ϩ Foxp3 ϩ Treg in recent years, CD8
ϩ Treg have also been reported to play important roles in neonatal tolerance (4) , tolerance to allograft (5) or xenograft (6) , and control of autoimmune diseases, including inflammatory bowel diseases and multiple sclerosis (7) (8) (9) . Adoptive transfer of CD8 ϩ Treg in rodents or induction of CD8 ϩ Treg in humans have been demonstrated to suppress allograft rejection and to prevent experimental autoimmune encephalomyelitis and autoimmune diabetes (9, 10) , suggesting that the endogenous enhancement of CD8
ϩ Treg activity or their adoptive transfer has great potential for the treatment of autoimmunity, allograft rejection, or graft-vs-host disease. Since Ag-specific Treg have higher efficiency and greater specificity for the regulation without the general suppression compared with polyclonal Treg, Ag-specific rather than polyclonal Treg are particularly promising as a means of human immunotherapy (11) . However, the clinical application of Treg immunotherapy is hampered by a lack of specific surface markers for Ag-specific Treg and difficulties in isolating and expanding these relatively rare cells. Several types of adaptive CD8 ϩ Treg have been described in human, such as Qa-1-dependent CD8 ϩ Treg subsets (12) (13) (14) . However, the expressions of these surface markers, particularly CD25 and CD45RO, and the lack of CD28 surface expression suggest that these cells are in an "activated" or "memory" state rather than that associated with a regulatory function (15) (16) (17) . Furthermore, it is still not known whether these different subsets of inducible CD8 ϩ Treg are distinct cell populations, partially overlapping ones, or are essentially derivatives from a common precursor cell type.
Although several approaches for induction of Ag-specific CD8 ϩ Treg have been reported, in which CD8 ϩ T cells were cocultured with allogeneic APC or Ag-pulsed autologous APC (18 -20) , there is currently no reliable protocol for the ex vivo induction and large-scale expansion of human alloantigen-specific CD8
ϩ Treg. On the other hand, staphylococcal enterotoxin B, anti-CD3 mAb with or without anti-CD28 mAb, autologous monocytes plus GM-CSF and IL-2, or IL-10 and IL-2 have been used to induce polyclonal human CD8
ϩ Treg (21, 22) but not Ag-specific cell populations. Recently, Gilliet et al. reported that human alloantigen-specific CD8 ϩ IL-10 ϩ Treg could be induced by allogeneic CD40-activated plasmacytoid dendritic cells (pDC). However, it is difficult to expand these CD8 ϩ IL-10 ϩ Treg because of their poor ability to mount secondary proliferation (18) .
Compared with pDC, using CD40-activated B cells for Treg induction has obvious advantages in that they can be readily expanded in vitro to relatively large numbers, retain their function after cryopreservation, and are relatively cost-effective to produce (23) . Additionally, since B cells stimulated with CD40L-transfected cells or recombinant soluble CD40L (sCD40L) were equally effective at generating alloantigen-specific CD4
ϩ Treg, the use of sCD40L may significantly improve the clinical applicability of the procedure. Taking advantage of the properties of CD40-activated B cells, we previously developed a novel protocol to induce and expand highly efficient human alloantigen-specific CD4
ϩ Treg from naive precursors on a large scale by using allogeneic CD40-activated B cells as stimulators (24) .
In this study, we found that CD40-activated B cells could also induce two T cell subsets with different levels of CD8 surface expression: CD8 high or CD8 low from naive CD8 ϩ CD25 Ϫ T cells. Although both CD8 high and CD8 low T cells had suppressive and cytolytic capacities that were mediated via different mechanisms, only CD8
high Treg exerted their suppressive and cytotoxic activities in an Ag-specific manner. The potency of CD8 high Treg suppression was significantly higher than their cytolytic activity. These CD8 high alloantigen-specific Treg exhibited memory (CD45RO ϩ ) surface phenotype and also expressed Foxp3, CD25, CD27, and CD28, as well as the lymph node homing receptor CD62L (L-selectin), but they lacked CCR7 expression. Importantly, CD8
high Treg could be expanded at a large scale, and the induction and expansion of these cells by allogeneic CD40-activated B cells were dependent on endogenously expressed IFN-␥, IL-2, IL-4, and CTLA-4.
Materials and Methods

Generation of CD40-activated B cells
Human peripheral blood was obtained from healthy donors in accordance with local ethical committee approval. B cells from PBMC were stimulated via CD40 using NIH3T3 cells transfected with the human CD40L (tCD40L cells) as described previously (24) . Briefly, PBMC were cocultured with the lethally irradiated (96 Gy) tCD40L cells in the presence of IL-4 (2 ng/ml; R&D Systems) and cyclosporine A (5.5 ϫ 10 Ϫ7 M) in IMDM (Invitrogen) supplemented with 10% heat-inactivated human AB serum, 50 g/ml transferrin (Boehringer Mannheim), 5 g/ml insulin (Sigma-Aldrich), and 15 g/ml gentamicin (Invitrogen) at 37°C in 5% CO 2 . After 14 days of coculture, Ͼ95% of the viable suspended cells are CD19
ϩ . B cells were cryopreserved for future use. For coculture with CD4 T cells, CD40-activated B cells were always Ficoll-density centrifuged followed by washing with PBS twice to remove nonviable cells, including remaining tCD40L cells.
T cell isolation
Human naive CD8 ϩ and CD4 ϩ CD25 Ϫ T cells were isolated from healthy donor PBMC by negative selection using a naive CD8 ϩ T cell isolation kit or a CD4 ϩ T cell isolation kit (Miltenyi Biotec) for depletion of CD4, CD14, CD16, CD19, CD36, CD56, CD123, TCR␥/␦, CD235a, and CD45RO (for naive CD8 ϩ T cells) or depletion of CD8, CD14, CD16, CD19, CD36, CD56, CD123, TCR␥/␦, and CD235a (for CD4 ϩ T cells). The CD25 ϩ cells were further depleted by positive selection with directly conjugated anti-CD25 magnetic microbeads (Miltenyi Biotec) following double-column depletion procedures. After depletion of CD25 ϩ cells, the purity of CD8 ϩ CD45RA ϩ CD45RO Ϫ CD25 Ϫ cells were routinely Ͼ99% as determined by flow cytometric analysis.
Allogeneic stimulation assay to induce and expand Treg
Freshly purified CD8 ϩ CD45RA ϩ CD45RO Ϫ CD25 Ϫ T cells were cocultured with allogeneic CD40-activated B cells at a T-to-B cell ratio of 10:1 in RPMI 1640 medium with 10% heat-inactivated human AB serum. For some experiments, T cells were labeled with CFSE before the coculture with CD40-acitvated B cells. In the repeated stimulation experiments, the allogeneic CD40-activated B cells were added every 7 days of culture. Functional and phenotypic hallmarks of the induced and expanded T cells were examined at indicated times. The expansion of the cells was determined by counting trypan blue negative aliquots.
Flow cytometric analysis
The phenotypes of cells were analyzed by a FACSAria. The following fluorescence-conjugated mAbs were used: anti-CD4-Alexa 405, anti-CD8-PE-Cy7, anti-CD45RA-PE, anti-CD45RO-allophycocyanin (Caltag Laboratories), and anti-CD25-allophycocyanin, anti-CD62L-allophycocyanin, anti-CD27-PE, anti-CD28-PE, anti-CCR7-PE (BD Biosciences), and their isotype-matched control Abs of irrelevant specificity were purchased from BD Biosciences. Intracellular staining was performed after cell fixation and permeabilization as we described before (25, 26) , and the following mAbs were used: anti-glucocorticoid-induced TNF receptor (GITR)-PE, anti-IL-10-PE (R&D Systems), anti-TGF-␤-PE (IQ Products), anti-CTLA-4-PE, anti-perforin-PE, anti-granzyme A-PE, anti-granzyme B-FITC, anti-IFN-␥-FITC, and anti-TNF-␣-FITC (BD Biosciences). For Foxp3 staining, the human Foxp3 staining kit (eBioscience) was used as we described before (24) .
MLR assay
The suppressor capacity of allogeneic CD40-activated B cell-induced and -expanded cells was studied in an MLR coculture suppression assay as we described before with some modifications (24 
Cytotoxicity assay
Cytotoxic capacity of the induced and expanded cells was determined by the Live/Dead cell-mediated cytotoxicity kit (Molecular Probes) (24) . Similar coculture system as described in "MLR assay" was set except that PBMC were not irradiated but labeled with 3,3Ј-dioctadecyloxacarbocyanine perchlorate (DiO), while responder CD4 ϩ CD25 Ϫ T cells were labeled with anti-CD4-Alexa 405. After 6 h of culture with propidium iodide, cells were analyzed by flow cytometry. Back gating on the green (DiO-PBMC) and blue (Alexa 405-CD4) fluorescent target cells, the propidium iodidepositive cells were evaluated for the percentage of dead cells.
Transwell assay
The cell-cell contact dependency of CD8 high T cells function was examined by using a Transwell culture system. Briefly, 2 ϫ 10 5 autologous CD4 ϩ CD25 Ϫ cells were cocultured with 2 ϫ 10 5 allogeneic PBMC (for cytotoxicity) or 2 ϫ 10 5 ␥-irradiated allogeneic PBMC (for MLR) in the lower compartment of the cell culture wells while 4 ϫ 10 6 CD8 high T cells (for cytotoxicity) or 2 ϫ 10 5 CD8 high T cells (for MLR) were cultured in the Transwell inserts (0.4 m pore size; Millicell; Millipore). On hour 6 (for cytotoxicity) or day 3 (for MLR) after coculture, the percentage of dead targets or proliferation of autologous CD4 ϩ CD25 Ϫ cells was measured as described above. Moreover, to discriminate the cell-cell contact dependency of recognition from that of execution stages, we replaced intact CD8 high T cells with activated ones, which were sorted from the coculture with autologous CD4 ϩ CD25 Ϫ cells and allogeneic PBMC 2-4 h after coculture.
Blocking assay
Blocking studies were performed in the presence of the neutralization mAbs against CTLA-4 (1 g/ml; Ancell), IL-10 (1 g/ml; eBioscience), GITR (2 g/ml; R&D Systems), TGF-␤ (0.5 g/ml; R&D), IFN-␥ (2 g/ ml; R&D Systems), TNF-␣ (2 g/ml; R&D Systems), FasL (10 g/ml; R&D Systems), IL-2 (1 g/ml; eBioscience), IL-4 (2 g/ml; eBioscience), or their relevant isotype controls. The blocking perforin and granzyme assay was performed with concanamycin A (CMA) (10 g/ml; SigmaAldrich) and Bcl-2 (2 g/ml; R&D Systems).
Results
Novel CD8 ϩ Treg subsets with different levels of CD8 surface expression are induced by CD40-activated B cells
Ϫ T cells (purity Ͼ99%) were cocultured with allogeneic CD40-activated B cells without exogenous cytokines for 12 days. Interestingly, a new subset with substantially higher levels of CD8 surface expression (CD8 high ) compared with those basally was induced after 9 days of allostimulation (Fig. 1A) . Another new subset with significantly decreased levels of CD8 surface expression (CD8 low ) was induced after 12 days of allostimulation (Fig.  1A ). Accompanying these changes of CD8 expression, CD25 and Foxp3 expressions were also significantly up-regulated in alloantigen-stimulated CD8 high T cells, whereas alloantigenstimulated CD8 low T cells had only modest levels of CD25 and Foxp3 expression (Fig. 1A) . Most CD8 high and CD8 low T cells had undergone seven or eight cell divisions by 12 days of allostimulation (Fig. 1A) . In contrast, most T cells that retained basal levels of CD8 expression (hereafter referred to as CD8 mid T cells) had not undergone mitosis.
To determine the origin of CD8 low T cells, the CD8 high and CD8 mid T cells after 9 days of allostimulation were sorted by FACS and cocultured with the original CD40-activated B cells for another 3 days. Interestingly, CD8 low T cells were induced from CD8 high rather than from CD8 mid T cells after stimulation with CD40-activated B cells (supplemental Fig. S1 ). 4 We also determined the secondary proliferative capacities of these CD8 ϩ subsets after sorting on day 12 of allostimulation and found that CD8 high and CD8 low T cells had significantly higher proliferative capacities compared with CD8 mid T cells, and CD8
high T cells had the highest proliferative capacity (supplemental Fig. S2 ). CFSE staining showed that a major fraction of CD8 low T cells (Ͼ60%) experienced seven or eight divisions, whereas only 36% of CD8 high T cells underwent seven or eight divisions (Fig. 1A) , suggesting that most CD8 low T cells might be converted directly from CD8 high T cells. Taken together, our results suggest that CD8 low T cells may be mainly derived from CD8 high T cells and this differentiation is accompanied by mitosis.
Only CD8 high T cells are alloantigen-specific Treg
To determine whether the CD8 ϩ T cell subsets induced by CD40-activated B cells were suppressive, the MLR assay was used. As shown in Fig. 1B, CD8 high , CD8 mid , and CD8 low T cells generated by 12 days of allostimulation and sorted by FACS were added to autologous CD4 ϩ CD25 Ϫ T cells (responder cells) and allogeneic irradiated PBMC (stimulator cells) in the MLR system. Both CD8 mid and CD8 low T cells inhibited the proliferation of responder T cells in response to allogeneic stimulator cells derived from the same donor used for CD40-activated B cells, hereafter referred to as the Treg priming donor. However, both subsets also inhibited the MLR proliferation in which third-party allogeneic PBMC were used, although the suppressive effect of CD8 mid T cells in this context was lower than that of CD8 low T cells. In contrast, CD8 high T cells significantly inhibited the proliferation of responder T cells induced by allogeneic PBMC from the Treg priming donor, but had little effect on third party-mediated allogeneic stimulation of the responder T cells (Fig. 1B) . Importantly, these CD8 high T cells had potent suppressive potential: even at a ratio as low as 1:512 for CD8 high T cells to the autologous responder T cells (CD4 ϩ CD25 Ϫ ), there was an obvious suppression (Fig. 1B) . At a CD8 high -to-responder T cell ratio of 1:1, priming alloantigenstimulated proliferation was almost completely inhibited (Fig.  1B ). These data demonstrate that CD8
high T cells are alloantigenspecific Treg. 4 The online version of this article contains supplemental material. low , CD8 mid , and CD8 high T cell subsets were added into MLR culture system as described in "MLR assay", and proliferations of responder CD4 ϩ CD25 Ϫ T cells corresponding to target Ag and third-party Ag were compared at different ratios of regulators to responders. Proliferation (y-axis) is shown for 3 days of MLR. The results shown are representative of four independent experiments.
Characteristics of CD8 ϩ T cell subsets induced by CD40-activated B cells
We further characterized the phenotype of the induced CD8 Ϫ , and only ϳ45% of these cells were CD27 ϩ ( Fig. 2A) . We next examined the expression of molecules previously implicated in the suppression of Treg, including CTLA-4, GITR, IL-10, and TGF-␤ by intracellular staining. Fig. 2B shows that significantly higher frequencies (ϳ10 -20%) of CD8
high Treg expressed CTLA-4, GITR, IL-10, and TGF-␤ compared with only ϳ3-8% of CD8 low T cells. In contrast, CD8 mid T cells only expressed minimal amounts of these four molecules.
As cytolytic activity has been proposed to mediate regulatory T cell function in some contexts (9, 29) , we determined the expression of perforin, granzymes A and B, IFN-␥, and TNF-␣ by CD8
ϩ T cells following 12 days of allostimulation. A relatively high proportion (17-22%) of CD8
high Treg expressed cytolytic granules (perforin, granzymes A and B) compared with only ϳ7-13% of CD8 low T cells. In contrast, the levels of expression of IFN-␥ and TNF-␣ in CD8 high and CD8 low T cells were similar. CD8 mid T cells had minimal to undetectable levels of these molecules (Fig. 2B) .
The alloantigen-specific suppression of CD8 high Treg is cell-cell contact dependent and requires alloantigen-specific stimulation
To understand the mechanisms of CD8
high Treg suppression, we determined whether CD8
high Treg-mediated suppression requires cell-cell contact. Suppression was completely lost when the responder T cells and stimulator allogeneic PBMC were physically separated from the CD8 high Treg in a Transwell culture system (Fig. 3A) . Once CD8 high Treg were activated by stimulator allogeneic PBMC (act CD8 high ) their suppression to the responder T cells was partially reversed, even when they were separated from the responder T cells by Transwell. Taken together, these data suggest that the suppression mediated by CD8
high Treg is dependent on cell-cell contact, requires alloantigen-specific stimulation, and soluble molecules released from activated CD8 high Treg contribute, in part, to their suppression.
The alloantigen-specific suppression of CD8 high Treg partially relies on IL-10, TGF-␤, GITR, and CTLA-4 expression, but not on cell-mediated cytotoxicity
To determine which molecules contributed to the alloantigen-specific suppression mediated by CD8
high Treg, we added neutralization mAbs against IL-10, TGF-␤, CTLA-4, and GITR into the culture of MLR. Blockade of cytokines partially inhibited the ability of CD8 high Treg to suppress the MLR, with Abs against IL-10, TGF-␤, GITR, and CTLA-4 reversing ϳ60, 26, 30, and 42% of the suppression, respectively (Fig. 3B) . These data indicate that all of the above cytokines contribute to the suppression mediated by CD8 high Treg. To investigate whether cytotoxicity was involved in the suppression mediated by CD8
high Treg, we first examined their cytotoxic activity in the MLR culture system. As shown in Fig.  3C, CD8 high Treg had no cytotoxic activity at the E:T ratio of 1:1. Furthermore, the addition of the perforin inactivator CMA, the granzymes A and B inhibitor Bcl-2, or neutralizing mAbs against FasL (CD95L), IFN-␥, and TNF-␣ into the culture of MLR did not reverse CD8 high Treg suppression in this context (Fig. 3D) . These results suggest that the suppression of CD8 high Treg is not dependent on their cytotoxicity, at least at a 1:1 ratio of Treg to target cells.
CD8 high Treg have alloantigen-specific cytotoxicity at a high ratio of Treg to target cells
We next determined the capacity of alloantigen-induced CD8 ϩ T cell populations to mediate cytotoxicity at relatively high ratios to their targets. As shown in Fig. 4, CD8 low and CD8 mid T cells showed a similar level of dose-dependent cytotoxicity, and they killed both autologous CD4 ϩ CD25 Ϫ T cells and PBMC from the priming allogeneic donor or a third-party donor. In contrast, CD8 high Treg only killed autologous CD4 ϩ CD25 Ϫ T cells and PBMC from the priming allogeneic donor at a relatively high (Ͼ5:1) ratio with respect to these target cells, but they did not exhibit cytotoxicity when PBMC came from a third party. These results indicate that CD8
high Treg have alloantigen-specific cytotoxicity only at a high ratio of Treg to target cells.
Alloantigen-specific cytotoxicity of CD8 high Treg requires alloantigen stimulation and is cell-cell contact dependent
To determine the mechanisms of cytotoxicity of CD8 high Treg, sorted CD8
high Treg were cocultured with autologous CD4 ϩ CD25 Ϫ T cells and/or PBMC from the priming allogeneic donor at a ratio of 20:1 for CD8 high Treg to target cells. Similar to the results shown in Fig. 4, CD8 high Treg killed both autologous CD4 ϩ CD25 Ϫ T cells and alloantigen PBMC in the coculture of MLR. However, in the absence of alloantigen PBMC in the coculture, CD8
high Treg had no cytotoxic activity against autologous CD4 ϩ CD25 Ϫ T cells (Fig. 5A) . Additionally, the cytotoxicity of CD8 high Treg against allogeneic PBMC was significantly reduced when there were no CD4 ϩ CD25 Ϫ T cells in the coculture (Fig. 5A) . Therefore, these data indicate that optimal alloantigen-specific cytotoxicity mediated by CD8 high Treg requires alloantigen stimulation, and CD4 ϩ T cells help. We then applied a Transwell culture system to determine whether the cytotoxicity of CD8
high Treg need the direct cell-cell contract. Similar to their suppression, the cytotoxicity of CD8 high Treg was almost completely lost when the autologous CD4 ϩ CD25 Ϫ T cells and alloantigen PBMC were physically separated from the CD8 high Treg (Fig. 5B) . Once CD8 high Treg were activated by alloantigen (act CD8 high ), they only showed a minor cytotoxic activity against CD4 ϩ CD25 Ϫ T cells and allogeneic PBMC when they were separated from the target cells by Transwell (Fig. 5B) . Additionally, the supernatants from the culture of the alloantigen-stimulated CD8 high Treg also exerted cytotoxic activities against CD4 ϩ CD25 Ϫ T cells and PBMC (supplemental Fig. S3 ). These data indicate that the cytotoxicity of CD8 high Treg is dependent on the cell-cell contact, and the soluble molecules released from activating CD8 high Treg also contribute, at least in part, to their cytotoxicity.
Alloantigen-specific cytotoxicity of CD8 high Treg is mediated by soluble molecules and the Fas/FasL pathway
To further understand which soluble molecules and pathways are involved in the cytotoxicity of CD8 high Treg, blocking assays were performed using the perforin inactivator CMA, the granzymes A and B inhibitor Bcl-2, or neutralizing mAbs against FasL, IFN-␥, and TNF-␣ (Fig. 5C) . CMA or neutralizing mAbs against FasL, TNF-␣, and IFN-␥ significantly inhibited the cytotoxicity of CD8
ϩ Treg, and ϳ70% of their cytotoxicity was blocked by a combination of CMA, Bcl-2, and neutralizing mAbs for FasL (Fig. 5C) . These results suggest that soluble molecules and Fas/FasL pathway are involved in the cytotoxicity of CD8 high Treg. 
CD8 high alloantigen-specific Treg can be continuously expanded by CD40-activated B cells on a large scale without loss of function
We examined the ability of 3 wk of coculture of naive CD8 ϩ
CD25
Ϫ T cells with allogeneic CD40-activated B cells to generate CD8 high Treg, in which freshly generated CD40-activated B cells were added weekly. As shown in Fig. 6A , ϳ9.8 ϫ 10 6 (range, 9.2-11.3 ϫ 10 6 ) of CD8 high Treg could be generated from every 1 ϫ 10 6 naive CD8 ϩ CD25 Ϫ T cells based on study of 10 healthy randomly selected adult blood donors. Furthermore, expansion of CD8 high Treg for 21 days in culture did not alter their suppressive ability and Ag specificity (Fig. 6B) . Additionally, these Treg still maintained Foxp3 and CD25 expressions (data not shown). These data demonstrate that CD40-activated B cells can induce and expand alloantigen-specific CD8 high Treg on a large scale.
The induction of CD8 high alloantigen-specific Treg by CD40-activated B cells is dependent on IFN-␥, IL-4, IL-2, and CTLA-4 expressions
To determine the mechanisms underlying the induction of alloantigen-specific CD8
high Treg by CD40-activated B cells, we added the neutralizing mAbs against IFN-␥, IL-2, IL-4, IL-10, TGF-␤, and CTLA-4 in the coculture of naive CD8 ϩ CD25 Ϫ T cells and allogeneic CD40-activated B cells. As shown in Fig.  7 , neutralization of IFN-␥, IL-2, IL-4, or CTLA-4 significantly blocked the generation of CD8 high Treg by 9 days of culture. However, blockade of IL-10 and TGF-␤ did not affect the generation of CD8 high Treg. These data indicate that the induction and expansion of CD8 high Treg is mediated by IFN-␥, IL-2, IL-4, and CTLA-4.
Discussion
In this study, we describe two novel CD8
ϩ T cell subsets induced by CD40-activated B cells with different levels of CD8 surface expression (i.e., CD8 high and CD8 low ), whereas only CD8 high T cells are Ag-specific Treg. Using allogeneic CD40-activated B cells, we are able to induce and expand large numbers of highly efficient alloantigen-specific CD8 high Treg. To the best of our knowledge, this is the first report to generate human Ag-specific CD8
ϩ Treg on a large scale. By repeated stimulation of naive CD8 ϩ CD25 Ϫ T cells with allogeneic CD40-activated B cells for 3 wk, we could generate ϳ9.8 ϫ 10 6 alloantigen-specific CD8
high Treg without loss of their suppressive function from every 1 ϫ 10 6 naive CD8 ϩ CD25 Ϫ T cells, which can typically be isolated from 10 -20 ml of peripheral blood. Therefore, this is a practical protocol for the generation of relatively large numbers of human Ag-specific CD8
ϩ Treg, which should facilitate the development of clinical immunotherapy based on the adoptive transfer of Treg. Based on their high efficiency in inhibition, even 10 ml of peripheral blood from donors could be enough for induction of enough CD8 high Treg for a single dose of transplantation.
Different from the previously reported CD8 ϩ T cells induced by allogeneic CD40L-activated monocyte-derived DC (DC1) or pDC in which DC1-induced CD8 ϩ T cells had potent cytotoxicity and secondary proliferation, as well as low suppressive ability to allogeneic targets, and whereas pDC-induced CD8 ϩ Treg had poor cytotoxicity and secondary proliferation and highly Ag-specific suppressive ability to allogeneic targets (18), the CD8 high and CD8 low T cells induced by allogeneic CD40-activated B cells had unique characteristics in terms of their capacities of secondary proliferation, suppression, and cytotoxicity. Both CD8 high and CD8 low T cells induced by allogeneic CD40-activated B cells had suppressive and cytolytic capacities, whereas only CD8 high Treg exerted their suppressive and cytotoxicity in an Ag-specific manner. In contrast, the CD8 high Treg expressed high levels of CD25 and Foxp3, whereas the CD8 low Treg only expressed medium levels of these common Treg molecules (Fig. 1) . These data suggest that CD8 high might be a marker for alloantigen-specific CD8 ϩ Treg. Importantly, the alloantigen-specific CD8 high Treg had highly secondary proliferative capacity, and thereby they are easy to be expanded on a large scale (supplemental Fig. S2 and Fig. 6 ).
The reasons underlying the marked difference in Ag specificity between CD8 high and CD8 low T cells are still unclear. One plausible explanation is that these two subsets represent different stages of CD8 ϩ T cell differentiation: CD8 high Treg may represent memory cells, which require specific Ag recognition to exert their function, whereas CD8 low T cells may represent effector cells, which can directly exert their function without further Ag recognition. Indeed, the fact that CD8 low T cells come from CD8
high Treg (supplemental Fig. S1 ) also supports this speculation.
The alloantigen-specific CD8 high Treg also showed unique phenotypes. Although both CD8 high and CD8 low Treg generated in our system were CD45RO ϩ and CCR7 Ϫ memory/effector cells, only FIGURE 4. CD8 high Treg had alloantigen-specific cytotoxicity at a high ratio of Treg to target cells. CD8 low , CD8 mid , and CD8 high were sorted after 12 days of allostimulation. Targets (T) (CD4 ϩ CD25 Ϫ and PBMC) were cocultured with different CD8 ϩ T cell subsets (E, effector) at different E:T ratios. Killing efficiency of CD8 ϩ T cell subsets was determined by propidium iodide staining and analyzed by FACS as described in "Cytotoxicity assay". The percentage of dead cells (y-axis) is shown for 6 h of cultures. Data for four different experiments are shown (n ϭ 4).
alloantigen-specific CD8
high Treg expressed high levels of lymph node homing receptor CD62L ( Fig. 2A) , which is different from the induced CD8
ϩ Treg reported by others (30 -32) . The expression of CD62L suggests that CD8
high Treg might potentially be useful for migrating to peripheral lymphoid tissues draining graft sites to suppress T cell-mediated allograft rejection and graft-vshost disease (24, 33, 34) . Differing from previous reports that costimulatory receptor CD27 could be used to discriminate the functional CD4
ϩ Treg and non-Treg (35), there was no difference about the CD27 expression between CD8
high Treg and CD8 mid T cells in our system. Another costimulatory receptor, CD28, was reported to be lost in the induced CD8
ϩ Treg (36). However, CD8
high Treg induced in our system expressed CD28, but CD8 low Treg did not. CD28 signaling was reported to be essential for T cell proliferation and survival (37). Therefore, the expression of CD28 on CD8 high Treg is important for Treg-based immunotherapy because it could be expanded through CD28 signaling. In fact, we also demonstrate that CD8 high Treg has much higher proliferative capacity than do CD8 low Treg, and it could be expanded on a large scale.
In functional analysis, we demonstrated that the alloantigenspecific CD8
high Treg generated from our system could completely block the alloantigen stimulated MLR. With these Treg, the marked suppressive effects could occur with as little as ϳ98 suppressors (1:512 ratios) in a culture of 50,000 responding CD4 ϩ CD25 Ϫ T cells and 50,000 allogeneic PBMC stimulators. These effects are more potent than those previously reported in CD8
ϩ Treg and even most CD4 ϩ Treg, in which the significant suppressions were only found at the ratio of 1:32 to 1:1 for Treg to responding cells (22, 38 -42) , and again they suggest the potential clinical utility of the CD8 high Treg in adoptive immunotherapy. The mechanisms of suppressive function are different depending on the type of induced CD8 ϩ Treg. We demonstrate the Ag-specific suppression of CD8 high Treg is cell-cell contact dependent, requires Ag-specific stimulation, and partially relies on IL-10, TGF-␤, GITR, and CTLA-4 expressions, consistent with previous observations of in vitro induced human CD8
ϩ Treg (43-45). Some previous studies have also suggested that the suppression of CD8 ϩ Treg may be mediated by their cytotoxicity (22) . However, we found that the suppression of CD8
high Treg in MLR is not dependent on their cytotoxicity at the ratio of 1:1 for Treg to target cells, which might result from the decrease in releasing of cytolytic substance and efficiency of cell-cell contact caused by the reduction of CD8 high T cells in the system. These functions would help reducing the dose of CD8
high Treg needed and avoiding general destruction in recipient organs caused by them. The same as for their suppressive activities, CD8
high Treg also have alloantigen-specific cytotoxicity, whereas the cytotoxicity of CD8 low T cells is Ag nonspecific. However, compared with their suppressive capacity in which even at a ratio of 1:512 for Treg to responding cells, CD8
high Treg significantly inhibited alloantigenstimulated proliferation, the potency of CD8 high Treg cytotoxicity was relatively poor because CD8
high Treg only exert their cytotoxicity at very high ratio of Treg to target cells (Ͼ5:1). Consistent with previous reports (9, 29), we found that alloantigen-specific cytotoxicity of CD8 high Treg is cell-cell contact dependent and requires alloantigen stimulation. We further demonstrated that perforin, granzymes A and B, IFN-␥, TNF-␣, and the Fas/FasL pathway mediated their cytotoxicity.
B cells as the weaker APC have been reported to expand CD4 ϩ Treg in mice (46). Recently, we also reported that human CD40-activated B cells can induce and expand CD4
ϩ Treg from naive CD4 T cells (24) . In this study, we first described that CD40-activated B cells can induce and expand alloantigen-specific CD8
high Treg on a large scale without any exogenous cytokines. Different from other reports that TGF-␤ and IL-10 are critical for the induction of Treg (18, 47, 48), we found that the induction and expansion of CD8
high Treg by CD40-activated B cells was not mediated by TGF-␤ and IL-10. Consistent with previous reports that IL-2 is critical to maintain Treg survival, we also found that IL-2 is essential for the expansion of CD8 high Treg. Moreover, we demonstrated that the induction and expression of CD8
high Treg were also dependent on IL-4, IFN-␥, and CTLA-4 expressions (Fig. 7) . This is the first report about the involvement of IL-4, IFN-␥, and CTLA-4 in the induction and expansion of Treg, although these cytokines have been reported to play important roles in Treg suppressions (49). Importantly, it was unnecessary to add any exogenous cytokines for inducing and expanding alloantigen-specific CD8
high Treg, because CD40-activated B cells can secrete substantial amounts of IL-2 (24), and CD8 ϩ T cells can express some IFN-␥, CTLA-4, and IL-4 (data not shown). This lack of requirement for exogenous cytokines could significantly reduce the cost for the generation of alloantigen-specific CD8 ϩ Treg. In conclusion, we have developed a simple and low-cost method by using allogeneic CD40-activated B cells to induce and expand highly efficient human alloantigen-specific CD8
high Treg with both suppressive and cytolytic capacities from naive CD8 ϩ CD25 Ϫ T cells on a large scale. This may facilitate the clinical applications of Treg-based immunotherapy for the treatment of allograft rejection, autoimmune diseases, and leukemia in the future. 
